Organization | Helse Bergen

Helse Bergen Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial

2014

NCT02096510

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Helse Bergen | Helse-Bergen HF

Active Ingredients

Drugs in Phase 4 Trials (1)

oxygen (1 trial)

Drugs in Phase 2 Trials (2)

ambroxol (1 trial)

Drugs in Other Trials (1)

whole blood (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Addison Disease (Phase 2)

Adrenal Hyperplasia, Congenital (Phase 2)

Adrenocortical Hyperfunction (Phase 2)

Adrenogenital Syndrome (Phase 2)

Dementia (Phase 2)

Hyperplasia (Phase 2)

Lewy Body Disease (Phase 2)

Stroke (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 4
# of Trial APIs: 4